Compugen
Compugen Discusses Additions to Informatics Infrastructure Underlying its Drug Discovery Business
Premium
This week, Compugen provided details about an informatics platform it is developing internally for identifying protein functional interaction sites as part of its efforts to discover functional monoclonal antibodies in oncology and immunology that can be used as therapeutic candi
Merck Serono, Compugen Form Joint Venture to Develop Genomic Tests for Drug-Induced Toxicity
Premium
Originally published July 2.
Merck Serono, Compugen Form Biomarker Discovery Firm
NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.
Compugen, DiscoveRx Collaborate to Commercialize Peptides for GPCR Targets
NEW YORK (GenomeWeb News) – Compugen and DiscoveRx today announced a collaboration to commercialize specially designed peptides matched with specific G protein-coupled receptor targets.
Compugen Q3 Loss Rises on R&D Expenses
NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its third quarter, the same as in the year-ago period.
Aug 2, 2011
No Q2 Revenues for Compugen
May 11, 2011
Compugen Cuts Q1 Loss Despite No Revenues
Feb 24, 2011
Feb 15, 2011
Compugen's Q4, FY 2010 Revenues Rise
Oct 26, 2010
Compugen Cuts Q3 Loss
Jul 27, 2010
Compugen's Q2 Revenues Rise on Collaboration Fees
Apr 23, 2010
New Products: Apr 23, 2010
Premium
Feb 9, 2010
Compugen Cuts Q4 Loss on Decreased Spending
Jan 4, 2010
Compugen Shares Soar in December; Helicos Falls
Dec 30, 2009
Compugen Raises $19M Through Equity Offering
Dec 28, 2009
Compugen Shares Spike for Second Time in a Week
Dec 23, 2009
Compugen to Screen Peptides for Pfizer
Oct 27, 2009